Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05253560
Other study ID # SZMC-0168-17
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date May 16, 2017
Est. completion date December 31, 2025

Study information

Verified date November 2023
Source Shaare Zedek Medical Center
Contact Ari Zimran, MD
Phone +972-509149149
Email azimran@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Objective of the trial. To define a sub-population which is at increased risk of developing Parkinson, beyond the fact of carrying Gaucher; in this sub-population the investigators shall conduct a comprehensive evaluation that includes a variety of non-invasive tests, whose purpose is to evaluate the state of the pre- Parkinson's disease signs, signs which can appear, even twenty years before the appearance of the disease, and also to compare them to a group of diagnosed Gaucher patients and a group of healthy people who are not carriers of Gaucher disease. A group of those carriers will be available for trial or for treatment, if there will be a medicine for the prevention of the development of Parkinson, obtainable.


Description:

The carriers, the healthy people and the Gaucher patients will undergo a number of non-invasive tests, which test the pre-Parkinson signs. The tests are based on various sense tests, blood tests, measuring of blood pressure, lying and standing, ultra-sound of the brain and a neurological test (test of the nervous system and various questionnaires).


Recruitment information / eligibility

Status Recruiting
Enrollment 600
Est. completion date December 31, 2025
Est. primary completion date January 16, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 40 Years to 75 Years
Eligibility Inclusion Criteria: - Willing to participate Exclusion Criteria: - PD patients - Dementia

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
The investigators aim to identify prodromal PD in a cohort of carriers of Gaucher disease.
Tests to help identify prodromal PD in a cohort of carriers of Gaucher disease

Locations

Country Name City State
Israel Michal Becker- Cohen Jerusalem Please Select...

Sponsors (1)

Lead Sponsor Collaborator
Shaare Zedek Medical Center

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Other Transcranial sonography (TCS) Transcranial sonography (TCS) is a useful noninvasive diagnostic tool to detect hyperechogenicity (SN+) of the substantia nigra area in the brain. The hyperechogenicity happens due to increased amounts of iron, reflecting a functional impairment. 8 years
Other Color discrimination test Color discrimination was analyzed using The Farnsworth-Munsell 100 hue test. The test includes four boxes with a fixed number of color shade caps with slight shade differences needed to be ordered correctly. The result of each box was entered into a computerized system and automated the total error score (TES) 8 years
Other Hyposmia by the Bit-A UPSIT smell test The shorter version of the UPSIT smell test (The University of Pennsylvania Smell Identification Test) was used to evaluate hyposmia using twelve cards, each with a different smell. 8 years
Other Orthostatic hypotension (OH) defined as a fall of at least 20 mmHg systolic or at least ten mmHg diastolic blood pressure by 3 min of active standing or head-up tilt 8 years
Other Montreal Cognitive Assessment (MoCA) evaluate the cognitive and mental aspects associated with PD. A Montreal Cognitive Assessment (MoCA) score of 26 and above was considered normal 8 years
Other NeuroTrax computerized battery. The NeuroTrax computerized battery (www.neurotrax.com) includes seven sections: memory, executive function, attention, information processing speed, visual-spatial, verbal function, and motor skills 8 years
Other Beck Depression Inventory self-administered questioner including 21 questions used to screen, diagnose, and measure the severity of depression. 8 years
Other Frontal lobe assessment battery (FAB). evaluates executive dysfunction 8 years
Other rapid eye movement (REM) Idiopathic rapid eye movement sleep behavior disorder is an important risk factor in the diagnosis of PD. The REM questionnaire was completed by the participant. 8 years
Other Epworth sleepiness scale (ESS) assessing daytime sleepiness includes an eight-question questionnaire scoring between 0 and 24; the higher the score, the higher the chances of dosing off 8 years
Other Perdue pegboard. Perdue pegboard measures the movement of fingers, hands, and arms in 4 different tasks, testing motor abilities and coordination by placing as many pegs and discs on a board in three 30 seconds trials for each subset and three 60 second trials for the assembly subset 8 years
Other UPDRS part III. measures gross motor function. A score above 6, not including postural and action tremor, was considered abnormal 8 years
Other The Timed Up and Go (iTUG). The Timed Up and Go (iTUG) (EncephaLogTM) is a platform that utilizes smartphones' internal motion sensors for conducting motor evaluation including general walking score, step to step persistency, hand sway and rotation time. 8 years
Other Questionnaire regarding risk factors Spontaneous bowel movement frequency was used to define constipation. Urinary and erectile dysfunction were assessed according to the MDS criteria 8 years
Primary Building a model to identify carriers of Gaucher disease prone to Parkinson's disease, using tests to assess different domains of PD, including anatomy, cognitive and mental, sleep disorder, and motor. Carriers of a variant in the GBA1 gene (GBA carriers) are at the highest risk of developing Parkinson disease (PD). A screening study for prodromal PD features in a cohort of obligatory GBA carriers between 40-75 years was initiated to identify candidates for a PD prevention trial. We added healthy controls and GD patients in order to determine the incidence of prodromal PD and for analyzing the differences between the two groups helping to build a model for identifying at risk PD at the prodromal stage.
Participants preform 15 pre-defined non-invasive tests for prodromal PD and assessment of risk factors. Risk factors for PD included age, sex, type of GBA1 variant, coffee and tea caffeine consumption, smoking habits, exposure to solvents and pesticides, and family history of PD (1st and/or 2nd degree relatives with PD).
8 Years
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1